Scinai Immunotherapeutics Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SCNI Nasdaq 2834 www.scinai.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scinai Immunotherapeutics Ltd.

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Sep 8th, 2026 7:15 am
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum - Aug 24th, 2026 5:00 am
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Aug 10th, 2026 4:34 am
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Jun 10th, 2026 5:55 am
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - May 20th, 2026 5:00 am
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - May 15th, 2026 5:30 am
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Apr 24th, 2026 6:00 am
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Apr 1st, 2026 5:00 am
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Mar 19th, 2026 5:50 am